Want to see ATR full AI Analyst Report?
ATR Stock Chart & Stats
$132.36
$0.52(0.39%)
At close: 4:00 PM EDT
$132.36
$0.52(0.39%)
Day’s Range― - ―
52-Week Range$103.23 - $158.12
Previous CloseN/A
Volume117.25K
Average Volume (3M)449.70K
Market Cap
$8.55B
Enterprise Value$9.30K
Total Cash (Recent Filing)$197.27M
Total Debt (Recent Filing)$1.19B
Price to Earnings (P/E)23.9
Beta0.54
Next Earnings
Oct 29, 2026EPS Estimate
1.48Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)5.60
Shares Outstanding63,820,316
10 Day Avg. Volume448,899
30 Day Avg. Volume449,698
Financial Highlights & Ratios
PEG Ratio3.61
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$152.50Price Target Upside15.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)5.49
Revenue Forecast (FY)$3.98B
Bulls Say, Bears Say
Bulls Say
Pharma Segment Resilience & Regulatory ValidationPharma demand excluding a one-off emergency medicine drop grew 8%, and regulatory approvals for PMDI and other platforms validate Aptar's tech. This creates durable, high-margin design‑in relationships with pharma customers that sustain recurring revenue and support premium pricing over months.
Improving Leverage And Capital BaseDeclining leverage and rising equity increase financial flexibility, lowering refinancing risk and enabling continued capex, R&D, and shareholder returns. A stronger balance sheet supports multi‑quarter investments in capacity and product qualification cycles that underpin long‑term revenue.
Consistent Revenue Growth And ScaleMulti‑year top‑line expansion and a record quarter reflect diversified end markets and volume scale. Steady revenue growth strengthens manufacturing utilization and spreads fixed costs, supporting sustainable operating profitability and capacity to fund new product programs over the medium term.
Bears Say
Margin CompressionRecent margin deterioration driven by mix, higher input costs, and operational inefficiencies compresses operating profitability. If mix shifts or cost pressures persist, sustained margin erosion would reduce free cash generation and limit reinvestment or returns over coming quarters.
Moderate Cash ConversionFCF covering only half of reported earnings and recent declines indicate weaker cash conversion. This reduces spare cash for acquisitions, capex, or buybacks and makes funding growth or smoothing cyclical costs more dependent on maintaining margins and disciplined working capital management.
Emergency Medicine Destocking HeadwindA sizable, concentrated destocking event (~$65M) creates near‑term revenue and margin volatility and highlights exposure to lumpy product categories. Recurrent or similar customer inventory swings could cause uneven earnings and complicate capacity planning for several quarters.
AptarGroup News
ATR FAQ
What was AptarGroup, Inc.’s price range in the past 12 months?
AptarGroup, Inc. lowest stock price was $103.23 and its highest was $158.12 in the past 12 months.
What is AptarGroup, Inc.’s market cap?
AptarGroup, Inc.’s market cap is $8.55B.
When is AptarGroup, Inc.’s upcoming earnings report date?
AptarGroup, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were AptarGroup, Inc.’s earnings last quarter?
AptarGroup, Inc. released its earnings results on Jul 30, 2026. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.354 by $0.066.
Is AptarGroup, Inc. overvalued?
According to Wall Street analysts AptarGroup, Inc.’s price is currently Undervalued.
Does AptarGroup, Inc. pay dividends?
AptarGroup, Inc. pays a Quarterly dividend of $0.48 which represents an annual dividend yield of 1.43%. See more information on AptarGroup, Inc. dividends here
What is AptarGroup, Inc.’s EPS estimate?
AptarGroup, Inc.’s EPS estimate is 1.48.
How many shares outstanding does AptarGroup, Inc. have?
AptarGroup, Inc. has 63,820,316 shares outstanding.
What happened to AptarGroup, Inc.’s price movement after its last earnings report?
AptarGroup, Inc. reported an EPS of $1.42 in its last earnings report, beating expectations of $1.354. Following the earnings report the stock price went up 0.067%.
Which hedge fund is a major shareholder of AptarGroup, Inc.?
Currently, no hedge funds are holding shares in ATR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AptarGroup Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$152.50 (15.22% Upside)
$152.50 (15.22% Upside)
Blogger Sentiment
Bullish
ATR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 709.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.25%
12-Months-Change
Fundamentals
Return on Equity
1.43%
Trailing 12-Months
Asset Growth
5.50%
Trailing 12-Months
Company Description
AptarGroup, Inc.
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
ATR Company Deck
ATR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of clear positives — record quarterly revenue, resilient pharma performance (8% ex‑emergency medicine), strong consumer healthcare growth, product/IP/regulatory milestones, sustainability recognition, and active shareholder returns — alongside tangible near‑term headwinds: emergency medicine destocking (~$65M FY impact), margin compression (EBITDA and EPS declines), operational issues in beauty and closures, higher costs and a higher tax rate. Management emphasized progressive operational improvements and confidence in long‑term growth drivers, but acknowledged short‑term dilution to margins and EPS. On balance the narrative is constructive about the company's fundamentals and future pipeline, while being transparent about cyclical and operational challenges that temper near‑term profitability.View all ATR earnings summariesATR Stock 12 Month Forecast
Average Price Target
$152.50
▲(15.22% Upside)
Technical Analysis
Baxter International
―
Cooper Co
―
Repligen
―
West Pharmaceutical Services
―
Stevanato Group
―
Ownership Overview
0.79% Insiders
31.04% Mutual Funds
6.73% Other Institutional Investors
35.45% Public Companies and
Individual Investors